公开(公告)号：WO2009079225A1

公开(公告)日：2009-06-25

申请号：PCT/US2008/085622

申请日：2008-12-05

Applicant: ABBOTT LABORATORIES ,  LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D. ,  TIAN, Zhenping ,  BRACKEMEYER, Paul J.

Inventor： LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D. ,  TIAN, Zhenping ,  BRACKEMEYER, Paul J.

IPC: C07D295/14 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  A61K31/40 ,  A61K31/41 ,  A61K31/44 ,  A61P25/00

CPC classification number: C07D401/12 ,  C07D207/06 ,  C07D207/08 ,  C07D207/12 ,  C07D213/82 ,  C07D295/14 ,  C07D295/155 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D417/10 ,  C07D417/12 ,  C07D495/04

Abstract: Compounds of formula (I) wherein R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , and R 5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 其中R1，R2，R3，R3a，R3b，R4和R5在说明书中定义的式（I）化合物可用于治疗组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。

公开(公告)号：WO2007150010A2

公开(公告)日：2007-12-27

申请号：PCT/US2007/071849

申请日：2007-06-22

Applicant: ABBOTT LABORATORIES ,  LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D.

Inventor： LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D.

IPC: C07D207/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/10 ,  C07D495/04 ,  A61K31/4025 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4365 ,  A61K31/454 ,  A61K31/4196 ,  A61K31/397 ,  A61K31/55 ,  A61P25/00

CPC classification number: C07D207/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/10 ,  C07D495/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 式（I）化合物可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法，以及制备式（I）范围内的化合物的方法。

公开(公告)号：WO2009085945A1

公开(公告)日：2009-07-09

申请号：PCT/US2008/087413

申请日：2008-12-18

Applicant: ABBOTT LABORATORIES ,  BLACK, Lawrence A. ,  COWART, Marlon D. ,  GFESSER, Gregory A. ,  WAKEFIELD, Brian D. ,  ALTENBACH, Robert J. ,  LIU, Huaqing ,  ZHAO, Chen ,  HSIEH, Gin C.

Inventor： BLACK, Lawrence A. ,  COWART, Marlon D. ,  GFESSER, Gregory A. ,  WAKEFIELD, Brian D. ,  ALTENBACH, Robert J. ,  LIU, Huaqing ,  ZHAO, Chen ,  HSIEH, Gin C.

IPC: A61K31/423 ,  A61K31/428 ,  C07D413/14 ,  C07D417/14 ,  A61P25/00 ,  A61P3/10

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D417/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Abstract translation: 式（I）化合物可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了式（I）化合物的药物组合物，使用这些化合物和组合物的方法及其制备方法。

公开(公告)号：WO2009082698A1

公开(公告)日：2009-07-02

申请号：PCT/US2008/087729

申请日：2008-12-19

Applicant: ABBOTT LABORATORIES ,  RUETER, Lynne E. ,  FOX, Gerard B. ,  BROWMAN, Kaitlin E. ,  SULLIVAN, James P. ,  BRIONI, Jorge D. ,  COWART, Marlon D. ,  FAGHIH, Ramin ,  GFESSER, Gregory A. ,  MORTELL, Kathleen H. ,  GOPALAKRISHNAN, Murali

Inventor： RUETER, Lynne E. ,  FOX, Gerard B. ,  BROWMAN, Kaitlin E. ,  SULLIVAN, James P. ,  BRIONI, Jorge D. ,  COWART, Marlon D. ,  FAGHIH, Ramin ,  GFESSER, Gregory A. ,  MORTELL, Kathleen H. ,  GOPALAKRISHNAN, Murali

IPC: A61K31/00 ,  A61K45/06

CPC classification number: A61K45/06 ,  A61K31/165 ,  A61K31/40 ,  A61K2300/00

Abstract: The present invention relates to compositions for treatment of cognitive deficits. Such compositions can have a nicotinic acetylcholine receptor ligand, of either α4ß2 subtype or α7 nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture. Combinations of such active agents with psychostimulants or monoamine reuptake inhibitors also is contemplated.

Abstract translation: 本发明涉及用于治疗认知缺陷的组合物。 这样的组合物可以具有a4β2亚型或a7烟碱型乙酰胆碱亚型的烟碱型乙酰胆碱受体配体，组胺3受体配体，使用该配体的方法和相关制品。 也考虑了这些活性剂与精神兴奋剂或单胺再摄取抑制剂的组合。

公开(公告)号：EP2237779A1

公开(公告)日：2010-10-13

申请号：EP08867156.5

申请日：2008-12-18

Applicant: Abbott Laboratories

Inventor： BLACK, Lawrence A. ,  COWART, Marlon D. ,  GFESSER, Gregory A. ,  WAKEFIELD, Brian D. ,  ALTENBACH, Robert J. ,  LIU, Huaqing ,  ZHAO, Chen ,  HSIEH, Gin C.

IPC: A61K31/423 ,  A61K31/428 ,  C07D413/14 ,  C07D417/14 ,  A61P25/00 ,  A61P3/10

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D417/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

公开(公告)号：EP2049472A2

公开(公告)日：2009-04-22

申请号：EP07784511.3

申请日：2007-06-22

Applicant: ABBOTT LABORATORIES

Inventor： LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D.

IPC: C07D207/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/10 ,  C07D495/04 ,  A61K31/4025 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4365 ,  A61K31/454 ,  A61K31/4196 ,  A61K31/397 ,  A61K31/55 ,  A61P25/00

CPC classification number: C07D207/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/10 ,  C07D495/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 式（I）化合物可用于治疗由组胺-3受体配体预防或缓解的病症或障碍。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法以及制备式（I）范围内的化合物的方法。

公开(公告)号：EP2231631A1

公开(公告)日：2010-09-29

申请号：EP08861197.5

申请日：2008-12-05

Applicant: Abbott Laboratories

Inventor： LIU, Huaqing ,  BLACK, Lawrence A. ,  BENNANI, Youssef L. ,  COWART, Marlon D. ,  TIAN, Zhenping ,  BRACKEMEYER, Paul J.

IPC: C07D295/14 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  A61K31/40 ,  A61K31/41 ,  A61K31/44 ,  A61P25/00

CPC classification number: C07D401/12 ,  C07D207/06 ,  C07D207/08 ,  C07D207/12 ,  C07D213/82 ,  C07D295/14 ,  C07D295/155 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D417/10 ,  C07D417/12 ,  C07D495/04

Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Abstract translation: 其中R 1，R 2，R 3，R 3a，R 3b，R 4和R 5在说明书中定义的式（I）化合物可用于治疗由组胺-3受体配体阻止或缓解的病症或障碍。 还公开了包含组胺-3受体配体的药物组合物，使用这些化合物和组合物的方法以及制备式（I）范围内的化合物的方法。